Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Background & Aims: Glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies deliver histological benefit in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Multiple mechanisms may be important including weight loss, improved glycaemic control and putative direct...
Збережено в:
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2025-05-01
|
| Серія: | JHEP Reports |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2589555925000400 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|